HER targeting in HER2-Negative breast cancers: Looking for the HER3 Positive

Clinical Cancer Research

Volumn 21, Issue 13, 2015, Pages 2886-2888

  Campbell, Marcia R ^a   Moasser, Mark M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; KI 67 ANTIGEN; LAPATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRASTUZUMAB; TUMOR MARKER; TYROSINE KINASE RECEPTOR; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); CORRELATION ANALYSIS; DOWN REGULATION; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; PARACRINE SIGNALING; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; QUINAZOLINES;

EID: 84930403563     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3012     Document Type: Article

References (12)

1. Leary A, Evans A, Johnston SRD, A'Hern R, Bliss JM, Sahoo R, et al. Antiproliferative effect of lapatinib in HER2-positive and HER2-negative/HER3-high breast cancer: results of the presurgical randomized MAPLE trial (CRUK E/06/039). Clin Cancer Res 2015;21:2932-40
2. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
4. Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2010;28:1215-23
5. Campbell MR, Amin D, MoasserMM.HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010;16:1373-83
6. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human HER3 receptor. Proc Nat Acad Sci U S A 2009;106:21608-13
7. Wilson TR, Lee DY, Berry L, Shames DS, Settleman J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011;20:158-72
8. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995;10:1813-21
9. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008;358:1409-11
10. Tao JJ, Castel P, Radosevic-RobinN, Elkabets M, Auricchio N, AcetoN, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal 2014;7:ra29
11. Gordon V, Banerji S. Molecular pathways: PI3K pathway targets in triplenegative breast cancers. Clin Cancer Res 2013;19:3738-44
12. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43